Two ongoing German non-interventional studies (NIS) evaluate ofatumumab in relapsing multiple sclerosis (RMS) patients in routine clinical practice. RMS patients either receive ofatumumab as first-line therapy or after switching from any disease-modifying therapy (DMT).
No takes yet. Share an insight, caveat, or question.
Nelles et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: